

# 1 Analogous humoral antigen recognition 2 between Monkeypox-infected and Smallpox- 3 vaccinated individuals 4 5 6

7 Ashley D. Otter<sup>1\*†</sup>, Scott Jones<sup>1\*</sup>, Bethany Hicks<sup>1\*</sup>, Daniel Bailey<sup>2</sup>, Helen Callaby<sup>2</sup>, Catherine  
8 Houlihan<sup>2</sup>, Tommy Rampling<sup>2</sup>, Nicola Claire Gordon<sup>2</sup>, Hannah Selman<sup>1</sup>, Panayampalli S.  
9 Satheskumar<sup>3</sup>, Michael Townsend<sup>3</sup>, Ravi Mehta<sup>4</sup>, Marcus Pond<sup>5</sup>, Rachael Jones<sup>5</sup>, Deborah  
10 Wright<sup>6</sup>, Clarissa Oeser<sup>7</sup>, Simon Tonge<sup>8</sup>, Ezra Linley<sup>8</sup>, Georgia Hemingway<sup>1</sup>, Tom Coleman<sup>1</sup>,  
11 Sebastian Millward<sup>1</sup>, Aaron Lloyd<sup>1</sup>, Inger Damon<sup>3</sup>, Tim Brooks<sup>2</sup>, Richard Vipond<sup>6</sup>, Cathy  
12 Rowe<sup>1</sup>, Bassam Hallis<sup>6</sup>

13  
14  
15  
16 \* -contributed equally

17 † - corresponding author: [ashley.otter@ukhsa.gov.uk](mailto:ashley.otter@ukhsa.gov.uk)  
18  
19  
20

21 1 – Emerging Pathogen Serology group, UKHSA Porton Down, Wiltshire, UK

22 2 – Rare and Imported Pathogens Laboratory, UKHSA Porton Down, Wiltshire, UK

23 3 – Poxvirus and Rabies Branch, Centre for Disease Control and Prevention, Atlanta, Georgia, USA

24 4 – Imperial College Health Trust, London, UK

25 5 – Chelsea and Westminster Health Trust, London, UK

26 6 – Research and Development, UKHSA Porton Down, Wiltshire, UK

27 7 – Immunisation and Vaccine Preventable Diseases Division, UKHSA Colindale, London, UK

28 8 – Seroepidemiology Unit, UKHSA Manchester, Manchester, UK  
29  
30

## 31 **Abstract**

32 In early 2022, a cluster of Monkeypox (now termed MPOX) virus (MPXV) cases were identified  
33 within the UK with no prior travel history to MPXV-endemic regions, suggesting localised  
34 transmission of MPXV within the UK. Subsequently, cases were identified in several other  
35 non-endemic countries and currently exceed 80,000 worldwide, primarily affecting gay,  
36 bisexual, and other men who have sex with men. Public health agencies worldwide have  
37 offered the IMVANEX Smallpox vaccination to these individuals to provide protection and limit  
38 the spread of MPXV.

39 We have developed a comprehensive array of ELISA assays to study poxvirus-induced  
40 antibodies, utilising 24 MPXV and 3 Vaccinia virus (VACV) recombinant antigens. Panels of  
41 serum samples from individuals with one, two, or three doses of IMVANEX or ACAM2000  
42 (Modified Vaccinia Ankara (MVA)) vaccination, and those with prior MPOX infection were  
43 tested against these antigens, with Pearson correlation, principal component analysis and  
44 receiver operator curve statistics used to further elucidate antigenic responses to pox-virus  
45 infection. Furthermore, using our data, we demonstrated the development of a pooled antigen  
46 ELISA that can reliably detect antibody responses induced by Smallpox vaccination or MPXV  
47 infection.

48 Using diverse poxvirus antigen ELISAs, we observe that one dose of Smallpox vaccination  
49 induces a low number of antibodies, primarily against MPXV B2, with a second dose inducing  
50 considerably higher antibody responses against B2R but also to other MPXV antigens such  
51 as B5, E8, M1, and A35. Prior MPXV infection, both Clades IIa and IIb, induce variable  
52 responses, but similarly induce antibody responses to poxvirus antigens observed in  
53 Smallpox-vaccinated individuals, and additionally responses to MPXV A27, A29 and H3.  
54 Principal component and Pearson correlation matrix identified MPXV A27 as a differential  
55 between IMVANEX and MPOX-infected individuals, whilst MPXV M1 (VACV L1) is likely a  
56 serological marker of IMVANEX-vaccination. When using recombinant MPXV/VACV protein  
57 homologues, we also observe a difference in antigen binding, with variability based on the  
58 individual's originating infection/vaccination. Using a pooled-antigen ELISA, we also  
59 demonstrate a sensitivity of 97.14% (95% CI:91.93-99.22) and specificity of 98.23% (96.67-  
60 99.07) in detecting poxvirus antibodies with applicability to measuring longitudinal antibody  
61 responses post-vaccination/post-MPXV infection.

62 Here, we show that both MPXV-infected or Smallpox-vaccinated individuals mount antibodies  
63 able to bind a diverse but core set of poxvirus antigens, with implications for future vaccine  
64 (e.g., mRNA-based) and therapeutic (e.g., monoclonal antibodies) targets. We identify low  
65 levels of antibodies observed in those post dose one IMVANEX, but considerably higher levels

66 of antibodies post dose two. We also demonstrate that homologous VACV and MPXV antigens  
67 may offer a mechanism for discriminating between vaccinated and MPXV-infected individuals  
68 through differential binding, aiding in serosurveillance and future immunology studies.

## 69 Introduction

70

71 MPOX virus (MPXV), is a member of the Orthopoxviruses, a group of closely related viruses,  
72 some of which are highly pathogenic that cause distinctive diseases in humans and animals<sup>1-  
73 5</sup>. Within the Orthopoxvirus genus, other members of this viral family include Vaccinia virus  
74 (VACV), the foundation of a number of Smallpox vaccinations; Variola virus (VARV), the  
75 causative virus of Smallpox disease which was subsequently declared eradicated in 1980<sup>3,6</sup>;  
76 and Cowpox virus (CPXV), the virus likely used by Edward Jenner to inoculate individuals  
77 against Smallpox<sup>2,7</sup>. Whilst Orthopoxviruses share a high degree of genetic homology<sup>2,8</sup>, they  
78 vary in their pathogenicity to humans. VARV is highly pathogenic in humans, contributing to  
79 300-500 million historic deaths worldwide, with no known animal reservoir, aiding in its  
80 eradication. VACV can cause disease in humans<sup>9,10</sup>, however attenuated strains of VACV  
81 have been developed through serial passage, as the basis of a number of licensed vaccines  
82 against Smallpox – Dryvax<sup>®</sup>, ACAM2000 (both based on the New York City Board of Health  
83 vaccinia virus strain) and Modified Vaccinia Ankara (MVA) Bavarian Nordic (MVA-BN); trade-  
84 names 'IMVANEX' and 'JYNNEOS).

85 After the eradication of Smallpox in 1980<sup>6</sup>, routine Smallpox vaccination, using Vaccinia virus,  
86 was halted worldwide<sup>3,11</sup>. Since this vaccination programme stopped, it has been suggested  
87 that the worldwide population remain increasingly at risk of poxvirus infection, due to waning  
88 antibodies in those with prior Smallpox vaccination and a lack of vaccine-derived immunity in  
89 those born after 1980<sup>11,12</sup>.

90 MPXV is a zoonotic pathogen (with a presumed rodent animal reservoir) causing MPOX  
91 disease<sup>1,13,14</sup>. Previously, it has been identified only in central and Western African countries  
92 with occasional importations in returning travellers. There have been a small number of  
93 onward transmissions in some countries such as the UK<sup>15-17</sup> and USA<sup>18-20</sup>, however minimal  
94 mutations are observed between isolates spanning multiple years<sup>2</sup>.

95 In the UK on the 7th of May 2022, one case of MPXV was identified in a returning traveller  
96 from Nigeria. A week later, an autochthonous familial cluster was identified, with no link to the  
97 earlier case and no travel history outside of the UK to MPXV-endemic regions<sup>21,22</sup>. Shortly  
98 afterwards, further MPXV cases were identified in the UK, largely in gay, bisexual, and other  
99 men who have sex with men (GBMSM) with no travel to endemic countries or known exposure  
100 to confirmed cases. Thereafter, other non-endemic countries including the USA, Spain,  
101 Germany, Portugal and France also identified similar cases and evidence emerged of local  
102 transmission in these countries<sup>21</sup>. To date, >80,000 cases of MPXV have been identified  
103 globally<sup>23</sup>, the majority of which have been in GBMSM<sup>22</sup>. Whole genome sequencing has

104 identified 30-80 mutations in sequences from MPXV isolated during the current outbreak,  
105 which has been termed Clade IIb, compared to previous MPXV cases from Clade I or Clade  
106 IIa<sup>24-26</sup>. Mutations within Clade IIb were primarily either GA- to AA-, or TC- to TT substitutions,  
107 suggesting that host factors such as APOBEC3 cytosine modification led to these mutations,  
108 possibly due to sustained infection in a new host or altered phenotypic/transmission  
109 methods<sup>25,26</sup>.

110 To limit transmission during the 2022 MPXV outbreak, public health agencies recommend  
111 Smallpox vaccination, as previous studies have shown protection from MPOX disease using  
112 the Smallpox vaccines such as IMVANEX or ACAM2000<sup>27-31</sup>. The immunology of Dryvax®,  
113 ACAM2000 and IMVANEX vaccines has been well studied<sup>27,32-36</sup>, with antibody responses  
114 detected up to 35 years post-Smallpox vaccination<sup>34</sup>. However, studying the immunology to  
115 MPXV infection and disease has been limited by the geographical distribution, limited number  
116 of human cases worldwide and access to convalescent serum samples. Animal models have  
117 been undertaken to understand immunology from MPOX disease in species such as  
118 macaques<sup>28,31</sup> and prairie dogs<sup>27</sup>, however, the translation of this to human MPOX infections  
119 is unknown.

120 Whilst T-cell immune responses to MPOX infection have been studied during the current  
121 Clade IIb 2022 outbreak<sup>37,38</sup> and previous outbreaks<sup>39</sup>, we sought to determine the humoral  
122 response and antigen recognition induced by both Clade IIa and IIb MPXV infection, with  
123 comparisons to IMVANEX and ACAM2000 vaccinated individuals. Similarly, using a  
124 combination of data, we demonstrate the ability of a multi-antigen ELISA to study antibody  
125 responses in Smallpox-vaccinated or MPOX-infected individuals.

126

## 127 **Materials and methods**

128

### 129 **Serum samples from Smallpox vaccinated individuals**

130 Individuals with prior or imminent IMVANEX vaccination were recruited from UKHSA Porton  
131 Down. Written informed consent was given by each participant prior to sampling. Individuals  
132 in the process of receiving IMVANEX vaccination were bled before their primary intramuscular  
133 vaccination (n=18), then further bled at 24 days post dose one (n=8) and 14 (n=10), 43 (n=7),  
134 63 (n=8) and 84 days (n=7) post dose two. Two individuals with historical IMVANEX  
135 vaccination (>4 years prior) receiving a booster were bled 14 days post dose (n=2). In addition,  
136 serum samples were provided by the Poxvirus and Rabies Branch at the US Centre for  
137 Disease Control and Prevention (US-CDC) from individuals post ACAM2000 single dose  
138 vaccination (n=4) and multiple dose vaccination (n=1). Further detail can be found in **Table 1**.

139

### 140 **MPOX Convalescent serum**

141 Residual and anonymised MPOX convalescent serum from PCR-confirmed cases from the  
142 2022 Clade IIb outbreak (n=43) were obtained for diagnostic assay development from the  
143 Rare and Imported Pathogens Laboratory, Imperial College Healthcare NHS Trust, and  
144 Chelsea and Westminster Hospital NHS Foundation Trust. Date of birth was used a proxy for  
145 historic Smallpox vaccination (<1971), although noted that not all patients born prior to the  
146 end of the eradication programme may have been vaccinated. Days since diagnosis was also  
147 recorded. Convalescent MPOX Clade IIa sera from 2018 and 2019 (n=3) were obtained from  
148 the Rare and Imported Pathogens Laboratory from previous imported MPOX cases.

149

### 150 **Negative and confounder samples**

151 To determine pox-antigen reactivity and background pox-antibody reactivity, paediatric serum  
152 samples were sourced from the UKHSA Seroepidemiology Unit (SEU), Manchester (n=256).  
153 In addition, confounder serum samples from those with PCR-confirmed infection with CMV  
154 (n=99), EBV (n=100) and VZV (n=100) along with serum samples positive for Rheumatoid  
155 factor (n=100) were used to determine assay specificity.

156

### 157 **Antigens**

158 Recombinant MPX protein antigens were sourced from several commercial companies, as  
159 either Eukaryotic- or Prokaryotic- expressed proteins (**Table 2** and supplementary table 1) as  
160 follows: A14, A26, A27, A29, A36, A44, B5, B6, C15, C18, D13, D14, E8, F3 and L1  
161 (ProteoGenix, France), B2 and C19 (Abbexa, UK), A5L and L4R/VP8 (Native Antigen  
162 Company, UK) and A33, A35, H3, I1 and M1 (SinoBiological, China). MPXV sequences for  
163 recombinant protein expression were all based on Clade II.

164 Additionally, recombinant VACV Copenhagen protein antigens A27, A33 and B5 were sourced  
165 from SinoBiological.

### 166 **Single antigen ELISAs**

167 ELISAs utilising single MPXV or VACV antigens were all performed using the same method,  
168 with variation in the coating antigen only. Briefly, 48 wells of a Corning High-Binding 96-well  
169 plate were coated with 100 µl/well of 0.1 ug/ml recombinant antigen overnight at 4°C, with the  
170 other 48 wells 'coated' with PBS (Gibco, 10010). After overnight incubation, plates were  
171 washed three times with 300 µl/well of PBS with Tween20 (0.01% final) using a Biotek 405 TS  
172 plate washer before being blocked with 200 µl SuperBlock (ThermoFisher, 37516) for 60  
173 minutes at room temperature. Plates were washed again as before, serum samples were  
174 diluted to 1:200 in Superblock and 100 µl per well was applied to both the antigen-coated and  
175 PBS-only wells. After a 60-minute incubation with the samples at 37°C, plates were washed  
176 as before and 100 µl/well goat anti-human IgG preabsorbed H+L (AbCam, ab98624), diluted  
177 1:8000 in Superblock, was added to the plate. Plates were incubated for a further 60 minutes  
178 at 37°C, followed by a wash with 300 µl/well of PBS with 0.01% Tween20 five times. Plates  
179 were then developed with 50 µl/well 1-Step™ Ultra TMB-ELISA Substrate Solution  
180 (ThermoFisher, 34029) for 30 minutes at 37°C and stopped with 50 µl/well KPL TMB Stop  
181 Solution (Seracare, 5150-0021). Plates were then read at an absorbance of 450nm using a  
182 Infinite F50 plate reader (Tecan, 30190077).

183

### 184 **Pooled antigen ELISA**

185 A pooled-antigen ELISA was performed similarly to single antigen ELISAs described above,  
186 however, wells were coated with 100 µl/well of a pool of recombinant MPXV antigens A35, B2,  
187 B6 and E8, and recombinant VACV antigen B5, each at a concentration of 0.1 ug/ml. In  
188 addition, to determine endpoint titres, samples were also serially diluted 1:4 seven times in  
189 SuperBlock, starting at a 1:100 dilution and 100 µl added per well.

190

### 191 **Data Analysis**

192 Before analysis, the absorbances achieved on the PBS-only wells were subtracted from the  
193 corresponding absorbances achieved on the antigen-coated wells.

194 All data analysis (curve fitting, receiver operator curve, Pearson correlation or principal  
195 component analysis) was performed using GraphPad Prism 9.2.0 (GraphPad Software, USA)  
196 unless otherwise stated. For Pearson correlation, analysis was performed whereby  $r$  was  
197 computed for every pair of  $y$  data set and used to generate a correlation matrix. Data were  
198 assumed to have Gaussian distribution with  $p$ -values determined using the Two-tailed method.  
199 Principal component analysis was performed using the OD of each antigen for each sample

200 as a continuous variable and principal components were selected based on parallel analysis  
201 with 1,000 simulations performed at a 95% percentile level. The results of the principal  
202 component analysis were grouped by sample group.  
203 The endpoint titres of a sample were calculated by fitting a sigmoidal 4PL model to sample  
204 absorbances versus  $\log^{10}$  transformed sample dilution and interpolating the dilution at an  
205 absorbance of 0.1926.



206 **Table 1:** Overview of samples used in this study.

	Sample Group	n=	Median time since vax/inf (Days)	Range since vax/inf (Days)	Median age
Negatives	IMVANEX pre-vaccination	18	-	-	27
	ACAM2000 Pre-vaccination	5	-	-	N/A
	Paediatric negatives	256	-	-	3
Smallpox vaccinated	IMVANEX post-dose 1 (time point 1)	8	24	14	26
	IMVANEX post-dose 2 (time point 1)	10	14	14-28	27
	IMVANEX post-dose 2 (time point 2)	7	43	37-63	26
	IMVANEX post-dose 2 (time point 3)	8	63	63-85	26
	IMVANEX post-dose 2 (time point 4)	7	84	84-106	26
	ACAM2000 vaccinated	5	40	30-200-	23
MPOX	Convalescent MPOX (Clade <b>Ia</b> )	3	7	5-20	37
	Convalescent MPOX (Clade <b>Ib</b> )	43	81	20-113	37
Confounders	Confounder: CMV (aged ≤50)	62	N/A	N/A	34
	Confounder: CMV (aged ≥51)	37			63
	Confounder: EBV (aged ≤50)	54			25
	Confounder: EBV (aged ≥51)	46			62
	Confounder: Rheumatoid (aged ≤50)	82			15
	Confounder: Rheumatoid (aged ≥51)	18			63
	Confounder: VZV (aged ≤50)	58			32
	Confounder: VZV (aged ≥51)	42			60

207  
208

209 **Table 2:** MPXV antigens and their homologues in VACV and known or predicted functions.  
 210 Antigen in bold are recombinant antigens used in this study. <sup>1</sup> MPXV proteins labelled  
 211 according to the genome of MPXV virus Zaire-96-I-16 (NC\_003310). <sup>2</sup> VACV proteins  
 212 labelled according to VACV Copenhagen (M35027). Data obtained from<sup>40–44</sup>

<b>MPXV Protein<sup>1</sup></b>	<b>VACV Protein<sup>2</sup></b>	<b>VACV vs MPXV homology (%)</b>	<b>Type</b>	<b>Protein description/function</b>
<b>A5</b>	A4	95.0	Late	39-kDa immunodominant virion core protein
<b>A14</b>	A13	92.8	Late	IMV inner and outer membrane protein
<b>A26</b>	-	N/A	Late	Similar to cowpox A-type inclusion protein
<b>A27</b>	-	N/A	Late	N-terminal of A-type inclusion body protein of CPV, missing from MVA Bavarian Nordic (IMVANEX) strain
<b>A29</b>	<b>A27</b>	93.6	Late	Intracellular mature virus (IMV) surface membrane 14-kDa fusion protein, binds cell surface heparan
<b>A33</b>	A31	86.6	-	Unknown function, 53 bp insertion in MPXV C-terminus
<b>A35</b>	<b>A33</b>	96.1	Late	Extracellular enveloped virus (EEV) envelope glycoprotein, needed for formation of actin-containing microvilli and cell-to-cell spread
<b>A36</b>	A34	95.2	Late	EEV envelope glycoprotein, lectin-like, required for infectivity of EEV, formation of actin-containing microvilli, and cell-to-cell spread
<b>A44</b>	-	N/A	-	Unknown function, gene not predicted to be present in VACV Copenhagen, ACAM2000 or IMVANEX strains
<b>B2</b>	A56	93.0	Early-Late	EEV Type I membrane glycoprotein hemagglutinin, prevents cell fusion
<b>B5</b>	B4	93.1	-	Ankyrin-like
<b>B6</b>	<b>B5</b>	95.9	Early-Late	Palmitated 42-kDa EEV glycoprotein required for efficient cell spread and found on membrane of infected cells and EEV envelope, complement control protein-like
<b>C15</b>	F9	99.1	Late	MV membrane protein – required for virus entry
<b>C18</b>	F12	97.2	Early-Late	IEV, actin tail formation
<b>C19</b>	F13	98.7	Late	Major envelope antigen of EEV, wrapping of IMV to form IEV, phospholipase D-like
<b>D13</b>	C4	94.3	Early	Intracellular protein – inhibits NF-κB activation
<b>D14</b>	C3	93.1	Early	Secreted complement binding protein
<b>E8</b>	D8	94.7	Late	IMV surface membrane 32 kDa protein, binds cell surface chondroitin sulfate, IMV adsorption to cell surface
<b>F3</b>	E3	86.3	Early	IFN resistance, dsRNA binding, inhibits dsRNA dependent protein kinase, and 2-5A-synthetase
<b>H3</b>	H3	93.2	Late	IMV heparan-binding surface membrane protein
<b>I1</b>	I1	99.4	Late	Virosomal protein essential for virus multiplication
<b>L1</b>	J1	96.7	Late	IMV membrane protein – participates in virion morphogenesis
<b>L4</b>	J4	100	Early	RNA pol 22-kDa subunit
<b>M1</b>	L1	98.8	Late	Myristylated IMV surface membrane protein

## 214 Results

215

### 216 Antigen recognition is analogous between Smallpox-vaccinated and Monkeypox 217 convalescent individuals

218 In total 27 pox-virus antigens (24 MPXV and 3 VACV antigens), spanning diverse functions  
219 from structural viral proteins to those involved in virion morphogenesis and host  
220 immunomodulation (**Table 2**) were tested against a panel of serum samples of those with prior  
221 smallpox-vaccination or MPOX infection (**Figure 1**).

222

223 Of the negative samples, individuals demonstrated minimal antibody binding to all the MPXV  
224 or VACV antigens, with the exception of one individual, showing binding to the MPXV H3 and  
225 VACV A27 antigen. Binding to MPXV C18 was observed across all negative samples. In  
226 individuals that received one dose of the IMVANEX vaccine, antibody binding to MPXV and  
227 VACV antigens was generally low (post-dose 1 (PD1), **Figure 1**), however, all individuals  
228 generated antibodies post-vaccination that were able to bind the MPXV B2 (VACV A56)  
229 antigen. Antibody binding to the VACV B5 and the MPXV homologue; B6, was variable across  
230 individuals, only one individual demonstrated robust antibody binding to both the VACV-B5  
231 and MPXV-B6 antigens.

232

233 Two-dose IMVANEX vaccinated individuals (14-days post-vaccination) demonstrated diverse  
234 recognition of a number of MPXV and VACV antigens, with the strongest binding of antibodies  
235 observed to VACV B5 and MPXV B6, followed by MPXV antigens A35, B2, E8 and M1 (Post-  
236 dose 2, time point 1 (PD2.1), **Figure 1**). Some individuals had antibodies able to bind MPXV  
237 A5, A29 and H3, but absorbances were generally low, with the exception of MPXV A29 in  
238 which two individuals demonstrated strong binding. Following further time points, post-dose 2  
239 vaccination (43-, 63- and 84-days post-dose 2), lower binding to antigens was observed, in  
240 particular to MPXV antigens B2, A35, B6, E8 and M1, and VACV A33 and B5 demonstrating  
241 similar decreasing binding.

242

243 We were also able to sample two individuals that received two historical IMVANEX doses (>3  
244 years prior) with a booster (third) dose of IMVANEX (Post-dose 3 (PD3), **Figure 1**). These  
245 individuals show similar antibody binding to antigens as those in the post-dose 2 cohort, with  
246 strong antibody binding to the MPXV B6, E8, A35, H3 and M1 antigens, and the VACV A33  
247 and B5 antigens. ACAM2000 Smallpox vaccination similarly induced antibodies that could  
248 bind the same antigens as IMVANEX-vaccinated individuals, with the exception of the MPXV  
249 M1 antigen, whilst binding was observed to the MPXV A27 antigen, which was not observed  
250 in IMVANEX-vaccinated individuals.

251

252 Serum samples from individuals with prior MPOX infection were similar to those from post-  
253 vaccination individuals, primarily mounting antibodies that bind VACV B5, A27 and A33 and  
254 MPXV-B2, B6, A27, A35 and E8, with variable binding across different individuals to these  
255 antigens and others such as A5, A14, A29, M1 and H3 (**Figure 1**). Serum samples from  
256 individuals with confirmed MPOX disease prior to the 2022 outbreak (Clade IIa) displayed  
257 similar antibody binding to the same antigens as serum samples from individuals during the  
258 2022 outbreak (Clade IIb), notably A35, A27, B2 and B6, and VACV-B5, but variable binding  
259 to MPXV-A29 and A44. Notably, no difference in antigen recognition was observed between  
260 those aged <51 and >51, with the latter more likely to have had historical smallpox vaccination  
261 (**Supplementary Figure 1**).

262


263 Using Pearson correlation, trends in antibody binding to diverse MPXV and VACV antigens  
264 were determined (**Figure 2**). C18 was removed from the correlation analysis, as non-specific  
265 antibody binding was observed. Most negative samples correlated either strongly with one  
266 another or with minimal correlation, with some samples demonstrating poor correlation to other  
267 negative samples. Furthermore, minimal correlation of antibody binding was observed  
268 between negative serum samples and serum samples obtained from those post Smallpox  
269 vaccination and post-MPOX infection, with the exception of dose-one IMVANEX vaccinated  
270 individuals, who demonstrated variable correlation in antibody binding to those post  
271 ACAM2000 vaccination, post-dose 2 IMVANEX vaccination or post-MPOX infection.

272

273 Conversely, serum samples from those post two dose IMVANEX vaccination at four different  
274 time points (14-, 43-, 63- and 84-days) had the strongest positive correlation observed, both  
275 between individuals and over different time points, with decreasing correlation over time since  
276 second-vaccine dose (**Figure 2**). Serum from post two dose IMVANEX vaccinated also  
277 strongly and positively correlated with ACAM2000 vaccinated individuals and convalescent  
278 Clade IIa and IIb MPOX infection, again with similar, strong correlation to one another. MPOX-  
279 infected individuals were highly correlated to one another, but as described earlier, also  
280 strongly correlated with those post-Smallpox vaccinations. A negative correlation was  
281 observed between the negative samples and those ACAM2000 vaccinated, two-doses of  
282 IMVANEX, or MPOX-infected individuals. Significance of individual samples to one another  
283 using Pearson correlation can be found in **Supplementary Figure 2**.


284

285



287 **Figure 1:** Heatmap of ELISA results of serum samples from negative, vaccinated (IMVANEX or ACAM2000) or MPXV-infected individuals  
 288 using individual MPXV or VACV recombinant antigens. Colour scale represents the OD. **Top panel)** MPX antigens, split according to the  
 289 different sample groups. **Middle panel)** VACV antigens, split according to the different sample groups. **Bottom panel)** Using a pool of four  
 290 MPXV and one VACV recombinant antigens.

291  
 292  
 293



294  
295  
296  
297  
298  
299  
300  
301

**Figure 2:** Pearson correlation matrix of VACV and MPXV antigens in groups with no prior infection or smallpox vaccination (negatives), IMVANEX vaccinated, ACAM2000 vaccinated and convalescent MPXV-infected individuals. Correlation was performed using all MPXV/VACV antigens, with the exception of C18. PD: IMVANEX post-dose, 2.1; 14 days, 2.2; 43 days, 2.3 63 days and 2.4; 84 days.

302 **Correlation is observed between antibody binding to MPXV and VACV homologous**

303 Similarly, Pearson correlation was used again to determine the correlation between  
304 MPXV/VACV antigens across the different groups (**Figure 3A-C, Supplementary Figure 4**).  
305 MPXV and VACV protein homologues were strongly correlated with one another in all groups,  
306 including negative samples: VACV B5 with MPXV B6, VACV A33 with MPXV A35 and VACV  
307 A27 with MPXV A29, with the exception of MPXV A29 and VACV A27 in the negative samples.

308

309 In negative samples, a number of antigens significantly correlated to one another – including  
310 MPXV A26 and MPXV A14, MPXV C19 and MPXV A33, MPXV D13 and MPXV A27, however  
311 all of the samples in this group demonstrated minimal antibody binding to these antigens  
312 (**Figure 3A, Supplementary Figure 4**). However, within the Smallpox-vaccinated group  
313 (IMVANEX or ACAM2000), a positive correlation was observed between a number of MPXV  
314 antigens including B2 with A35, B6, E8 and M1, as well as VACV antigens A33 and B5 (**Figure**  
315 **3B**). Similarly, in the MPOX convalescent group, MPXV antigen B2 correlated strongly with  
316 MPXV antigens A35, B6, E8 and H3 but also with MPXV A27, and VACV antigens A27, A33  
317 and B6 (**Figure 3C**).

318

319 **Smallpox-vaccinated and MPOX-infected individuals mount a shared yet distinct**  
320 **antibody-binding repertoire**

321 Using antibody binding data of serum from individuals to the 24 MPXV and 3 VACV antigens,  
322 principal component analysis was performed to determine clusters in differential binding  
323 repertoires between pre-vaccination/negative individuals and that Smallpox vaccinated (Dose  
324 1 IMVANEX, Dose 2 IMAVENEX and ACAM2000), or with prior MPOX infection groups  
325 (Clades IIa and Clade IIb).

326

327 Antibody binding within the negative group all clustered similarly close to one another, whilst  
328 dose 1 IMVANEX vaccinated individuals similarly clustered both with one another but also with  
329 the negative samples (**Figure 3D**). Dose 2 IMVANEX vaccinated individuals showed distinct  
330 clusters, different from the negative samples, however, some of the IMAVNEX vaccinated  
331 individuals clustered towards the negative samples (later time points post-two dose  
332 vaccination, **Supplementary Figure 4**). MPOX convalescent individuals formed a distinct  
333 grouping separately from IMVANEX vaccinated or negative samples, however, displayed a  
334 degree of overlap with both of these groups. ACAM2000 vaccinated individuals were not  
335 distinctive, falling within the middle of the MPOX-convalescent samples but separate from the  
336 IMVANEX vaccinated samples (**Figure 3D**).

337



338 Using a biplot from the principal component analysis, individual antigens were highlighted as  
339 distinctive to particular groups (**Figure 3E**). For MPOX-infected individuals, MPXV antigen  
340 A27 was the most specific to the MPOX-infected and ACAM2000 vaccinated group, followed  
341 by MPXV A14, D13 and A26, as well as VACV A27. Antigens specific to the IMVANEX-  
342 vaccinated group were primarily MPXV M1, but also E8, A36 and VACV antigens B5 and A33.

343

### 344 **Using MPXV/VACV antigens as a differential for discriminating between MPOX and** 345 **Smallpox vaccination**

346

347 Based on a number of analyses (**Figure 1, Figure 3D-E**), several antigens show promise in  
348 being used to differentiate between Smallpox-vaccinated and MPOX-infected individuals. We  
349 performed ROC analysis on some of the singular antigens identified in analyses described  
350 here (MPXV A27 and MPXV M1) to determine their feasibility in discriminating between  
351 vaccinated and infected (**Figure 4, Table 3**). No significant difference ( $p=0.8708$ ) was  
352 observed in antibody binding between the negative and IMVANEX vaccinated group for  
353 antibodies binding MPXV A27, however, MPOX-infected individuals had significantly higher  
354 antibody responses ( $p<0.0001$ ) compared to negatives. Similarly, ACAM2000 individuals had  
355 significantly ( $p<0.0001$ ) higher antibodies to MPXV A27 than negatives (**Figure 4A**). Utilising  
356 the MPXV M1 antigen, only IMVANEX-vaccinated individuals had significantly higher  
357 ( $p<0.0001$ ) antibodies compared with the negative samples, ACAM2000 vaccinated, or  
358 MPOX-infected individuals (**Figure 4B**).

359


### 360 **Antigen exposure influences preferential binding to MPXV or VACV antigens**

361

362 In our initial experiments, we observed that Smallpox-vaccinated and MPX-infected individuals  
363 had similar binding to both the VACV B5 and the MPXV homologue B6 (**Figure 1**). Separating  
364 the Smallpox-vaccinated and the MPOX-infected groups, we observed preferential binding to  
365 the protein that individuals were either vaccinated or infected with, whereby Smallpox-  
366 vaccinated individuals bind VACV B5 better than the MPXV homologue B6 and skewed  
367 towards the B5 (VACV) axis (**Figure 5A**). Conversely, MPXV-infected individuals were found  
368 to bind MPXV B6 better than the VACV homologue B5, with the majority of samples skewed  
369 towards the B6 (MPXV) axis. The same was also observed for the VACV-A33 and MPXV-A35  
370 proteins(**Figure 5B**)., however, there was minimal antibody binding to either pox-virus antigen  
371 observed in MVA-vaccinated individuals and only in MPOX-infected individuals. Homologues  
372 MPXV A29 and VACV A27 however demonstrated binding that was relatively limited to MPOX-  
373 infected individuals and skewed towards binding VACV A27 than MPXV A29 (**Supplementary**  
374 **Figure 5**). MPOX-infected individuals aged  $\geq 51$  (and thus likely to have had prior-smallpox



375 vaccination if UK born) did not show increased binding towards the VACV-antigen and were  
376 similar to the MPXV-infected individuals <51 (**Supplementary Figure 6**).




377

378 **Figure 3:** Correlation of antibody binding between MPXV/VACV antigens in **A)** MPOX  
 379 convalescent and Smallpox-vaccinated individuals, **B)** Smallpox vaccinated individuals and  
 380 **C)** MPOX convalescent individuals. Coloured asterisks denote protein homologues between  
 381 MPXV and VACV. Significant p-values for each correlation can be found in Supplementary  
 382 figure 4. **D)** Principal component analysis of antibody binding to 23 MPXV and 3 VACV  
 383 recombinant antigens, plotted and coloured by group. Coloured circles represent all samples  
 384 within that cohort. **E)** Biplot of principal component analysis, highlighting that a number of  
 385 ELISAs using specific antigens can be used for each particular group. Note: C18L was  
 386 excluded from all correlation and principal component analysis due to non-specific antibody  
 387 binding.


388

389



390

391 **Figure 4:** Differential MPXV pox virus antigens used to determine **A)** Prior MPXV infection or  
392 ACAM2000 vaccination using MPXV A27, and **B)** recent IMVANEX vaccination using MPXV  
393 M1.



394

395 **Figure 5:** Differential binding to the **A)** VACV B5 and MPXV B6 and **B)** VACV A33 and  
396 MPXV A35 proteins between the MPXV-infected individuals and MVA-vaccinated (IMVANEX  
397 and ACAM2000) individuals. Those with MVA vaccination show stronger binding to the  
398 VACV B5 and A33 protein compared to the MPXV B6 and A35 homologue, whilst MPXV-  
399 infected individuals show higher binding to the B6 and A35 protein. Contour lines represent  
400 density of values.

401 **Only a subset of MPXV and VACV antigens are recognised longitudinally following**  
402 **IMVANEX vaccination, with waning observed**

403

404 Using a time course from IMVANEX vaccinated individuals, we assessed the antibody binding  
405 in these individuals; prior to vaccination, 28-days post-primary vaccination dose (post-dose 1  
406 (PD1) D24), 14-days post second dose (PD2 D14), 43-days post-second dose (PD2 D43) and  
407 63-days post second dose. The majority of individuals demonstrated no antibody binding to  
408 the majority of antigens tested, demonstrated in earlier observations (**Figure 1**), however,  
409 antibodies were able to bind nine antigens (MPXV antigens B6, B2, E8, A35, M1, A29 and  
410 VACV antigens: B5 and A33) across the time course (**Figure 6**). Antibodies induced after one  
411 dose of vaccination were minimal, primarily to MPXV B2, however, an induction of antibodies  
412 to all nine antigens was observed 14-days post-dose 2. Cross-reactive antibodies to MPXV  
413 C18 were observed across all time points.

414

415 Area under the curve (AUC) analysis identified nine antigens with a high AUC, with the  
416 exception of A27, which was likely MPXV-specific (**Table 3**). Using Dunnett's multiple  
417 comparison tests, we also identify a number of antigens that are significantly higher at the  
418 different timepoints post-IMVANEX vaccination or MPOX-infection compared to negative  
419 samples (**Table 3**). In particular, a number of MPXV antigens were significantly higher 14-  
420 days post-dose 2 than negative samples (A29 ( $p=0.0043$ ), A35 ( $p<0.0001$ ), E8 ( $p<0.0001$ )  
421 and M1 ( $p<0.0001$ )) that showed no significant difference at day 63 post-dose 2. Similarly,  
422 MPXV A27 and VACV A27 were not significantly different between negatives and post-  
423 vaccination, however, were significantly higher in MPOX-convalescent individuals compared  
424 with negatives ( $p<0.0001$ ). When comparing antigens overtime, we observed no significant  
425 correlation in antibody binding to any of the antigens relative to time since infection (data not  
426 shown).

427

428 Using individual antigens for detecting post-vaccination or post-MPOX-infection was assessed  
429 using ROC analysis (**Table 3**). We observed that individual antigens such as MPXV B2R,  
430 which had a sensitivity of 93.94% (95% CI: 80.39-98.92%) and specificity of 94.44% (95% CI:  
431 74.24-99.72%) using a cut-off  $OD_{450nm}$  of  $>0.1743$ , were well suited in detecting post-  
432 vaccination samples (both dose 1 and all time points for dose 2).

433

434 MPXV A27 was highly accurate in being able to discriminate MPXV-infected individuals, with  
435 ROC analysis demonstrating 93.02% sensitivity (95% CI: 81.77% to 97.65%) and 94.44%  
436 specificity (95% CI: 83.78% to 98.36%) using a cut-off  $OD_{450nm}$   $>0.1838$  (**Table 3**). MPXV M1  
437 gave a sensitivity of 72.73% (95% CI: 61.22% to 85.08%) and specificity of 94.44% (95% CI

438 74.24% to 99.72%) in detecting IMVANEX-vaccinated individuals using a cut-off of OD<sub>450nm</sub>  
439 >0.07125.

440

441 **Antibodies from MPXV-infected and Smallpox-vaccinated individuals can reliably be**  
442 **detected using a pooled antigen ELISA**

443 From the results of individual antigen testing, the dominant antigens recognised by MPXV-  
444 infected and Smallpox-vaccinated individuals (IMVANEX or ACAM2000) were highly similar:  
445 VACV antigens B5 and MPXV antigens A35, B2, B6 and E8. We sought to determine the  
446 feasibility in using a pool of these antigens as the basis of detecting pan-Poxvirus antibodies,  
447 preventing the requirement for use of whole-MVA/VACV or individual recombinant pox  
448 antigens. We explored the sensitivity and specificity of this pool and comparisons to individual  
449 antigen results.


450

451 Compared to individual antigens, higher ODs were obtained when samples were tested using  
452 the pool antigen ELISA, compared with individual antigens, with trends in increasing antibody  
453 titres following a second dose of vaccination, and waning observed 63 days post second dose  
454 (**Figure 6B**). This sensitivity and specificity of this pooled antigen ELISA was then further  
455 explored, to determine feasibility in detecting antibodies induced both by Smallpox vaccination  
456 and MPOX infection. An overall sensitivity of 97.14% (95% CI: 91.93% to 99.22%) and  
457 specificity of 98.23% (95% CI: 96.67% to 99.07%) was determined using ROC analysis  
458 (**Figure 6C**), with an OD cut off of 0.1926, based on testing the pooled antigen ELISA against  
459 a total of 613 samples: 508 negatives (paediatric negatives, pre-vaccination samples and  
460 confounders) and 105 positives (IMVANEX vaccinated (Dose 1 or Dose 2), ACAM2000  
461 vaccinated or MPOX infected (Clade IIa and IIb)). All samples tested positive by the pooled  
462 antigen ELISA, with the exception of two MPOX-infected individuals, however these  
463 individuals demonstrated no antibody binding to any of the MPXV/VACV antigens (**Figure 1**).  
464 AUC analysis identified the pool antigen ELISA as the highest AUC compared to any individual  
465 antigen but was also the only ELISA that show significantly higher results in post-dose 1  
466 vaccinated individuals compared to negative samples, further demonstrating the utility of this  
467 pooled antigen ELISA (**Table 3**). This assay could be further quantified by performing endpoint  
468 titres, serially diluting samples 1:4 until the cut off of 0.1926 was achieved (**Figure 6D, Table**  
469 **3**).

470

471 When using a combined antigen pool, this resulted in a potentiation of antibodies detected by  
472 ELISA (Lower panel, **Figure 1**). In general, all samples tested on the individual antigens had  
473 lower antibodies determined by OD measurement than the pooled antigen ELISA (**Figure 6E**),  
474 with linear regression models similarly demonstrating higher ODs in the pooled antigen ELISA

475 relative to the individual antigens (**Figure 6F**). When comparing ROC analysis, the highest  
476 sensitivity and specificity for detecting antibodies induced by Smallpox vaccination or MPOX-  
477 infection was in fact the pooled antigen ELISA, with 98.31% and 95.65% sensitivity, and  
478 98.23% and 98.03% specificity, respectively (**Table 3**).  
479



480

481

482 **Figure 6:** Longitudinal sampling of individuals receiving IMAVENEX vaccination against **A)** a  
 483 panel of 24 MPXV and 3 VACV antigens or **B)** Pooled antigen ELISA. **C)** Evaluation of the  
 484 pooled antigen ELISA to determine sensitivity and specificity. **D)** Using the pooled antigen  
 485 ELISA, endpoint titres were determined for positive groups. Comparison of the ELISA results  
 486 of MPXV-infected and Smallpox-vaccinated serum samples using individual antigens relative  
 487 to the pool of antigens **E)** split by antigen, or **F)** linear regression of individual antigen results  
 488 relative to pooled antigen ELISA results. Dotted lines represent the 95% confidence intervals.  
 489 Black lines represent  $X=Y$ .

490 **Table 3:** Statistical analysis of individual MPXV/VACV antigens in detecting Smallpox- or MPXV-specific antibody responses. Area under the curve analysis  
 491 was performed using longitudinal IMVANEX samples. Dunnett's multiple comparisons test were used for each group, relative to the negative control samples.  
 492 ROC-analysis was used to determine sensitivity and specificity of antigens in detecting antibodies induced by either Smallpox vaccination of MPOX-infection. \*  
 493 - non-specific binding was observed to C18. Those antigens listed in bold had at least one significant difference relative to the negative samples.

Virus	Protein	Area Under the Curve (IMVANEX)			Dunnett's Multiple Comparisons Test (versus negatives)					ROC Analysis (versus Pre-IMVANEX)					
		Total Area	Std. Error	95% Confidence Interval	PD1 D24	PD2 D14	PD2 D43	PD2 D63	MPX ≥2022	Smallpox Vaccine			MPOX Convalescent		
										Cut-off	Sensitivity (%)	Specificity (%)	Cut-off	Sensitivity (%)	Specificity (%)
MPXV	A5	0.3077	0.1728	0.000 to 0.646	ns	ns	ns	ns	ns	< 0.0417	66.67	61.11	> 0.2103	30.23	88.89
	A14	0.1477	0.06122	0.027 to 0.268	ns	ns	ns	ns	ns	< 0.0641	87.88	38.89	> 0.0699	58.14	77.78
	A26	0.05971	0.04553	0.000 to 0.149	ns	ns	ns	ns	ns	< 0.0010	63.64	55.56	> 0.1233	16.28	94.44
	<b>A27</b>	0.3266	0.3174	0.000 to 0.949	ns	ns	ns	ns	****	> 0.0527	33.33	77.78	> 0.1838	93.02	94.44
	<b>A29</b>	0.5752	0.714	0.000 to 1.975	ns	**	ns	ns	***	> 0.0438	27.27	94.44	> 0.0441	86.05	94.44
	A33	0.1653	0.04762	0.0712 to 0.259	ns	ns	ns	ns	ns	> 0.0809	24.24	94.44	> 0.0783	34.88	94.44
	<b>A35</b>	1.696	0.4814	0.752 to 2.639	ns	****	*	ns	****	> 0.0661	63.64	94.44	> 0.0661	95.35	94.44
	A36	0.7491	0.2666	0.227 to 1.272	ns	ns	ns	ns	ns	> 0.1685	42.42	77.78	< 0.0025	25.58	94.44
	A44	0.3298	0.3876	0.000 to 1.089	ns	ns	ns	ns	ns	> 0.0007	63.64	61.11	> 0.1228	23.26	94.44
	<b>B2</b>	3.446	0.4966	2.473 to 4.420	ns	****	****	***	****	> 0.1743	93.94	94.44	> 0.2002	93.02	94.44
	B5	1.018	0.6515	0.000 to 2.295	ns	ns	ns	ns	ns	< 0.1375	39.39	83.33	< 0.1010	41.86	88.89
	<b>B6</b>	3.98	1.119	1.787 to 6.172	ns	****	****	****	****	> 0.0516	87.88	94.44	> 0.0186	97.67	94.44
	C15	0.173	0.0447	0.085 to 0.261	ns	ns	ns	ns	ns	< 0.0130	24.24	94.12	< 0.0123	41.46	94.12
	C18*	2.573	0.3455	1.896 to 3.250	ns	ns	ns	ns	ns	> 0.8333	33.33	94.12	> 0.8421	39.02	94.12
	C19	0.08756	0.03286	0.023 to 0.152	ns	ns	ns	ns	ns	> 0.0448	30.3	94.44	> 0.0438	27.91	94.44
	D13	0.1751	0.0693	0.039 to 0.311	ns	ns	ns	ns	ns	> 0.0471	45.45	72.22	> 0.1163	37.21	88.89
	D14	0.08473	0.03667	0.013 to 0.157	ns	ns	ns	ns	ns	< 0.0059	57.58	77.78	< 0.0066	60.47	77.78
	<b>E8</b>	2.326	0.6156	1.120 to 3.533	ns	****	****	ns	***	> 0.1319	69.7	94.44	> 0.1257	88.37	94.44
	F3	0.1377	0.04353	0.052 to 0.223	ns	ns	ns	ns	ns	< 0.0296	54.55	58.82	> 0.0713	29.27	94.12
	H3	0.3635	0.3254	0.000 to 1.001	ns	ns	ns	ns	ns	> 0.0346	45.45	83.33	> 0.1922	51.16	94.44
I1	0.000525	0.001485	0.000 to 0.003	ns	ns	ns	ns	ns	> 0.0042	3.03	100	> 0.0052	30.95	100	
L1	0.07473	0.04909	0.000 to 0.171	ns	ns	ns	ns	ns	> 0.0248	18.18	94.44	> 0.0231	34.88	94.44	
L4	0.2374	0.1457	0.000 to 0.5230	ns	ns	ns	ns	ns	> 0.1103	15.15	94.44	< 0.0027	48.84	66.67	
<b>M1</b>	1.57	0.549	0.4943 to 2.646	ns	****	**	ns	ns	> 0.0254	72.73	94.44	> 0.0249	47.62	94.44	
VACV	A27	0.588	0.354	0.000 to 1.282	ns	ns	ns	ns	****	< 0.0116	21.21	94.12	> 0.3892	83.72	94.12
	<b>A33</b>	3.067	0.6535	1.786 to 4.348	ns	****	****	*	****	> 0.2249	72.73	94.12	> 0.1387	83.72	94.12
	<b>B5</b>	4.927	1.135	2.702 to 7.152	ns	****	****	****	****	> 0.1657	84.85	94.44	> 0.2354	74.42	94.44
<b>Pooled antigen ELISA</b>		6.968	0.8284	5.345 to 8.592	*	****	****	****	****	> 0.1926	98.31	98.23	> 0.1535	95.65	98.03



## 495 Discussion

496

497 MPXV was detected in a wide range of countries during the 2022 outbreak after the initial  
498 identification of cases within the UK. Vaccination strategies have been implemented through  
499 a number of public health agencies worldwide as means to limit the spread of the disease and  
500 protect individuals from infection. Here, we have demonstrated that antibody responses  
501 induced by two widely used and licensed Smallpox vaccines (IMVANEX and ACAM2000, post-  
502 dose 1, 2 and 3) and prior MPOX infection (both prior Clade IIa or the current 2022 Clade IIb  
503 outbreak) are similar and are able to bind a number of MPXV and VACV antigens. We also  
504 describe the development of a pooled antigen ELISA to study both Smallpox-vaccine and  
505 MPOX-infection antibody responses.

506

### 507 Analogous antigen recognition is observed between Smallpox-vaccinated and 508 Monkeypox-convalescent individuals

509 Using an array of 27 different pox-virus antigens (24 MPXV and 3 VACV), we observe that  
510 Smallpox-vaccination (be it IMVANEX or ACAM2000) induces a similar antibody response to  
511 those previously infected with MPOX, both Clades IIa and IIb. Minimal antibodies to the  
512 diverse pox-virus antigens were observed in negative samples, with all negative samples  
513 correlating positively to one another (**Figure 1, Figure 2**). Surprisingly, however, those with  
514 one dose of IMVANEX vaccination demonstrated minimal antigen binding, such as with  
515 negative samples, except for the presence of some antibodies able to bind MPXV B2 in one-  
516 dose vaccinated individuals, likely explaining the minimal and variable correlation observed in  
517 this group to other vaccinated or MPOX-infected groups (**Figure 2**). However, variations in  
518 Eukaryotic/Prokaryotic-expressed proteins also need to be further assessed to determine  
519 effects due to glycosylation. Furthermore, differences in delivery (subcutaneous vs  
520 intradermal) and dosing (full versus fractional dosage) of the IMVANEX vaccination may play  
521 additional roles in induction of antibody and antigen binding, which was not studied here and  
522 warrants further investigation.

523

524 Nevertheless, a lack of robust antibody responses after one dose of IMVANEX in previously  
525 unvaccinated individuals (aged <50) does not suggest a lack of protection, as recent studies  
526 have shown that vaccine efficacy against disease after one dose of IMVANEX has been  
527 suggested to be as high as 78% when comparing vaccinated with unvaccinated individuals<sup>45</sup>.  
528 However, one vaccination dose has been shown to induce low-neutralising antibodies<sup>46</sup>, likely  
529 suggesting a role of cellular or T-cell immunity not measured in this study but performed by  
530 others<sup>37-39</sup>.

531

532 Within our study, we demonstrate that a number of antibodies capable of binding diverse pox-  
533 virus antigens are induced by two-dose IMVANEX-vaccination or MPOX prior infection (Clade  
534 IIa and Clade IIb), with high correlation between individuals in these groups and to one another  
535 (**Figure 2**). Even though we only have three Clade IIa convalescent samples, we observe no  
536 difference in antigen recognition between a Clade IIa and IIb MPOX infection, which should  
537 be further explored to understand the role of mutations in Clade IIb and their possible role in  
538 transcriptional changes and hence antigen recognition after MPOX infection<sup>25,26</sup>.

539

540 However, whilst there is a high correlation between antibody binding to diverse MPXV/VACV  
541 antigens in two-dose IMVANEX-vaccinated and MPOX-infected individuals, distinctive but  
542 overlapping grouping are observed when performing principal component analysis (**Figure**  
543 **3D**) which is further narrowed with post-vaccination antibody waning (**Supplementary Figure**  
544 **4**). These data suggest a core set of antigens shared across repeated IMVANEX vaccination  
545 and a MPOX infection and similarity across viral epitopes by both the MVA-BN virus used in  
546 the IMVANEX vaccine and an MPXV infection<sup>37</sup>. This aligns with the observed protection  
547 afforded when MVA was used for vaccination against MPXV infection in macaques<sup>28,29</sup> or used  
548 in regions with high MPXV prevalence<sup>5</sup>. Prior studies have demonstrated a difference in  
549 neutralising titres between those infected with MPOX aged <48 and >48<sup>46</sup>, however, we see  
550 no discernible difference in antibody binding to all MPXV and VACV antigens measured in this  
551 study (**Supplementary Fig 1**) but similarly confirm the low level of IgG induced by single  
552 IMVANEX vaccination. When performing principal component analysis, antibody waning in  
553 two-dose IMVANEX-vaccinated individuals results in the harmonisation of IMVANEX  
554 vaccinated with MPOX-infected groups, preventing discrimination (**Figure 3D**,  
555 **Supplementary Figure 4**). This suggests that other additional assays will be required for  
556 differentiating between MPOX-infected and VACV-vaccinated individuals such as specific-  
557 antigens or an avidity assay.

558

559 Immunological signatures for MPOX infection were identified such as antibodies induced to  
560 the MPXV A27 protein (**Figure 3C**, **Figure 4E** and **Table 2-3**), a cowpox-like type A inclusion  
561 protein that is present in the strain used in the ACAM2000 vaccination and MPXV isolates but  
562 missing in MVA-BN (IMVANEX) and VACV Copenhagen. The absence of A27 in VACV  
563 Copenhagen and MVA-BN may provide the ability of MPXV A27 to be used as a differential  
564 assay in serosurveillance studies in countries such as the UK, that do not or have not  
565 previously used the ACAM2000 smallpox vaccine. However, further work is required to ensure  
566 that cross-reactivity of antibodies to MPXV A27 is not observed in those with other  
567 *Chordopoxvirinae* infections and that a MPXV A27 assay can be used to also detect prior

568 infection with MPXV Clade I that was not assessed here. Similarly, we also identify MPXV M1  
569 (VACV homologue L1) as a serological marker of IMVANEX-vaccination (**Figure 5B**), but  
570 antibodies able to bind M1 were observed in some MPOX-infected individuals, possibly due  
571 to prior Smallpox-vaccination. The reasoning for MPXV M1 (VACV L1); an IMV surface  
572 membrane protein that has shown to be protective against poxvirus challenge<sup>47-49</sup>, as a  
573 differential between IMVANEX vaccinated and MPOX-infected or ACAM2000 vaccinated is  
574 unknown, and warrants further investigation, as it is present in all VACV and MPXV strains,  
575 with >98% amino acid identity between VACV Copenhagen and MPXV Zaire.

576

577 Similarly, whilst individual antigens show distinct and differential binding, binding between  
578 VACV and MPXV homologous antigens is different depending on individuals having VACV  
579 vaccination or an MPXV infection (**Figure 5**). This is further supported by recent work that  
580 demonstrated Smallpox-vaccine naïve individuals (e.g. aged <48) neutralise MPXV better  
581 than VACV<sup>46</sup>, reinforcing a virus-specific immunological response that should be further  
582 explored in those with heterologous antigenic exposures.

583

584 We also observe a waning in antibodies at day 84 post two doses, with a decrease in  
585 antibodies able to bind the diverse antigens observed at 14 days post two doses and endpoint  
586 titres using a pooled antigen ELISA (**Figure 2, Figure 6**). The further extent of this antibody  
587 and antigen-specific waning is to be explored, as others have demonstrated waning to  
588 individual antigens<sup>50</sup>, whilst persistence of IgG and neutralising antibodies up to 88 years post-  
589 vaccination have been observed<sup>51</sup>. Further work is needed to study the immunogenicity and  
590 persistence of antibodies to diverse pox-virus antigens after MPOX infection and/or IMVANEX  
591 vaccination, as means to provide data on antibody persistence and inform recommendations  
592 for future vaccination boosters in communities at-risk of MPOX transmission or infection. We  
593 are now also pursuing an understanding of the immunological impact of heterologous (both  
594 full and partial dosage) antigen exposure in those with MPOX infection followed by two  
595 IMVANEX doses, to understand antibody persistence and repertoire.

596

597 The presence of antibodies able to bind MPXV C18 (VACV F12), an IEV actin tail formation  
598 protein<sup>52</sup>, across all samples suggests either cross-reactivity of antibodies to the recombinant  
599 antigen or non-specific sequestration of immunoglobulins. Further work is ongoing to  
600 understand antibody binding and MPXV C18.

601

602 **A pooled MPXV and VACV antigen ELISA is sensitive and specific than individual**  
603 **antigens**

604

605 To perform reliable immunological studies on Smallpox vaccination, MPOX infection or  
606 serosurveillance, standardised and highly congruous ELISA assays are needed. Whilst a  
607 number of pox virus ELISAs use whole-MVA or inactivated VACV, this method requires virus  
608 growth and quality control with batch-to-batch variability. Using the data from our antigen  
609 panels, we describe the development of a pooled-antigen ELISA using commercially available  
610 recombinant antigens to study Smallpox-vaccine- and MPXV-induced antibody response.

611

612 Using a number of pre-vaccination/negative samples, longitudinal samples from IMVANEX  
613 vaccinated individuals, those with prior ACAM2000 vaccination but also MPOX-infected  
614 individuals, we demonstrate the use of nine antigens in detecting antibody responses in each  
615 of these groups (**Table 3**, MPXV antigens B6, B2, E8, A35, M1, A29 and VACV antigens: B5  
616 and A33). Whilst some of these antigens are highly sensitive and specific to detecting  
617 Smallpox-vaccination- or MPOX-infection-induced antibodies, the highest achieved was a  
618 pool of five antigens (MPXV B2, B6, E8, A35 and VACV B5). This pooled antigen assay  
619 demonstrates high sensitivity and specificity but also potentiation in antibodies detected than  
620 singular antigen ELISAs (**Figure 1, Figure 6E-F**). Furthermore, quantitation through endpoint  
621 titres is possible and enables quantification of antibody responses following vaccination and  
622 MPOX infection (**Figure 6D**).

623

624 The high sensitivity and specificity of the pool are explained by the recombinant antigen  
625 components: MPXV B2 (VACV homologue A56) is an EEV Type I membrane glycoprotein  
626 hemagglutinin that is integral for *in vivo* and *in vitro* spread of VACV, as well as binding  
627 additional VACV proteins in infected cell membranes<sup>53-55</sup>. MPXV E8 (VACV homologue D8)  
628 is an IMV surface membrane protein, shown to be involved in virus entry through binding  
629 chondroitin sulphate, eliciting strong humoral immunity<sup>56,57</sup>. MPXV B6 (and VACV homologue  
630 B5) is a 42-kDa EEV outer surface antigen, previously shown to be a major target of EEV-  
631 neutralising antibodies<sup>47,58,59</sup>, likely explaining the immunogenicity observed to MPXV B6 and  
632 VACV B5 in this study. Similarly, MPXV A35 (VACV homologue A33) is an EEV envelope  
633 protein and also a source of EEV protective antibodies<sup>47,58</sup>, whilst also previously  
634 demonstrated to be associated with B5<sup>60</sup>. Previous studies have also demonstrated anti-A33  
635 (MPXV A35) and anti-B5 (MPXV B6) monoclonal antibodies (mAbs) as protective against  
636 lethal VACV-challenge in mice<sup>61,62</sup>, however combinations of anti-VACV mAbs afforded the  
637 highest protection. These proteins are highly conserved between VACV and MPXV<sup>49</sup> (**Table**  
638 **2**), likely suggesting minimal changes in assay sensitivity if VACV homologues were used,  
639 however, based on differential binding demonstrated here (**Figure 4, Supplementary Figure**  
640 **5 and 6**), this should be further explored.

641

642 As a number of antibodies are induced to these antigens due to MPOX-infection, further work  
643 is warranted to determine if a combination of these antigens provide protection from disease  
644 as next-generation Smallpox vaccines. Prior work has similarly demonstrated that some of  
645 these antigens (both individually or combined) induce a robust antibody response when used  
646 in an mRNA<sup>63,64</sup> or DNA<sup>47-49</sup> vaccine, some of which have demonstrated protection against  
647 disease. Similarly, monoclonal antibodies against some of these antigens may provide new  
648 post-exposure or long-lasting therapeutics for MPOX or broad poxvirus disease, in  
649 replacement of convalescent serum such as VIG or recombinant VIG<sup>61,62,65</sup>.

650

### 651 **Strengths and weaknesses of this study**

652

653 One of the major strengths of this study is that we used a large number of whole recombinant  
654 MPXV/VACV antigens, some of which are produced in mammalian cells, which are more  
655 representative of viral proteins (including glycosylation) than linear peptides used in protein  
656 arrays. Furthermore, using 24 MPXV antigens, this covers ~15% of proteins encoded within  
657 the MPXV genome. Further work is now ongoing to perform expression and purification of all  
658 MPXV antigens to determine the range of antibodies involved in antigen binding induced by  
659 infection/vaccination using customised-multiplex assays (e.g., Luminex) to determine binding  
660 to whole proteins rather than linear epitopes using protein microarrays. Additional VACV  
661 homologues are also being sought to provide additional information on the preferential  
662 binding.

663

664 Our pooled antigens are skewed towards MPXV, though the data demonstrated here show  
665 that this pool is the only assay (compared to individual antigens) capable of detecting a  
666 statistically significant increase in antibodies relative to negative controls. Further optimisation  
667 of this antigen pool is ongoing to determine optimum antigens for use in vaccination  
668 immunology studies and serosurveillance.

669

670 Similarly, we did not conduct MVA, VACV or MPXV neutralisation as part of this study,  
671 however, our observations of low antibodies induced post one-dose of IMAVENX correlates  
672 to observations by others<sup>46</sup>. Further work is needed to understand the role of binding and  
673 neutralising antibodies in the context of correlates of protection.

674

675 Finally, the samples we used within this study were a diverse mix of vaccination/MPOX  
676 samples from individuals at differing time points, however further time points are required to  
677 monitor waning in both the vaccination and MPOX-vaccinated individuals, as well as  
678 assessing antibody persistence in those with heterologous antigenic exposure.

679 **Conclusions**

680

681 Here, our results provide a wealth of information on the immunology of MPOX infection, but  
682 also demonstrate analogous humoral antigen binding between those with Smallpox-  
683 vaccination (IMVANEX or ACAM2000) and those with prior MPOX infection (both Clade IIa  
684 and IIb). Furthermore, the singular proteins identified in this study in the immunological  
685 responses to both Smallpox vaccination and MPOX-infection may offer new targets for future  
686 vaccination strategies (e.g., mRNA vaccines) or therapeutics (e.g., mAbs). Similarly, using the  
687 analogous immune responses between Smallpox-vaccinated and MPOX-convalescent, we  
688 developed a highly sensitive and specific pooled antigen ELISA that offers a mechanism for  
689 reliably measuring immune responses post-infection or post-vaccination without the need for  
690 whole-virus ELISAs or live-virus neutralisation. These together offer an opportunity for the  
691 development and assessment of next-generation vaccinations.

692

693 **Funding**

694 This work was funded by the UK Health Security Agency, with additional funding obtained  
695 from the Coalition for Epidemic Preparedness Initiative (CEPI) for the development of a  
696 MPOX/Smallpox ELISA assay.

697

698 **Acknowledgements**

699

700 We would like to thank members of the CEPI, in particular Valentina Bernasconi, Mark Manak  
701 and Ali Azizi for their guidance throughout the development of the pooled antigen ELISA  
702 assay. We also are thankful to members of the Chelsea and Westminster and Imperial College  
703 Healthcare trusts that helped in obtaining MPOX-convalescent serum.

704



## 705 References

- 706 1. Lansiaux, E., Jain, N., Laivacuma, S. & Reinis, A. The virology of human monkeypox  
707 virus (hMPXV): A brief overview. *Virus Res.* **322**, (2022).
- 708 2. Dabrowski, P. W., Radonić, A., Kurth, A. & Nitsche, A. Genome-wide comparison of  
709 cowpox viruses reveals a new clade related to variola virus. *PLoS One* **8**, 79953  
710 (2013).
- 711 3. Shchelkunov, S. N. Emergence and reemergence of smallpox: The need for  
712 development of a new generation smallpox vaccine. *Vaccine* **29**, D49–D53 (2011).
- 713 4. Malshetty, V. S., Jain, R., Srinath, T., Kurthkoti, K. & Varshney, U. Synergistic effects  
714 of UdgB and Ung in mutation prevention and protection against commonly  
715 encountered DNA damaging agents in *Mycobacterium smegmatis*. *Microbiology* **156**,  
716 940–949 (2010).
- 717 5. Priyamvada, L. & Satheshkumar, P. S. Variola and Monkeypox Viruses (Poxviridae).  
718 *Encycl. Virol.* **2**, 868–874 (2021).
- 719 6. Strassburg, M. A. The global eradication of smallpox. *AJIC Am. J. Infect. Control* **10**,  
720 53–59 (1982).
- 721 7. Smith, K. A. Edward Jenner and the small pox vaccine. *Frontiers in Immunology* **2**, 21  
722 (2011).
- 723 8. Goebel, S. J. *et al.* The complete DNA sequence of vaccinia virus. *Virology* **179**, 247–  
724 266 (1990).
- 725 9. Lewis, F. M. T. *et al.* Ocular vaccinia infection in laboratory worker, Philadelphia,  
726 2004. *Emerg. Infect. Dis.* **12**, 134–137 (2006).
- 727 10. Silva-Fernandes, A. T. *et al.* Natural human infections with Vaccinia virus during  
728 bovine vaccinia outbreaks. *J. Clin. Virol.* **44**, 308–313 (2009).
- 729 11. Pennington, H. Smallpox and bioterrorism. *Bulletin of the World Health Organization*  
730 **81**, 762–767 (2003).
- 731 12. Hammarlund, E. *et al.* Duration of antiviral immunity after smallpox vaccination.  
732 (2003). doi:10.1038/nm917
- 733 13. Weaver, J. R. & Isaacs, S. N. Monkeypox virus and insights into its  
734 immunomodulatory proteins. *Immunological Reviews* **225**, 96–113 (2008).
- 735 14. Wilson, M. E., Hughes, J. M., McCollum, A. M. & Damon, I. K. Human monkeypox.  
736 *Clin. Infect. Dis.* **58**, 260–267 (2014).
- 737 15. Vaughan, A. *et al.* Two cases of monkeypox imported to the United Kingdom,  
738 september 2018. *Eurosurveillance* **23**, 1800509 (2018).
- 739 16. Vaughan, A. *et al.* Human-to-human transmission of monkeypox virus, United  
740 Kingdom, October 2018. *Emerg. Infect. Dis.* **26**, 782–785 (2020).
- 741 17. Hobson, G. *et al.* Family cluster of three cases of monkeypox imported from Nigeria to  
742 the United Kingdom, May 2021. *Eurosurveillance* **26**, 2100745 (2021).
- 743 18. Karem, K. L. *et al.* Characterization of acute-phase humoral immunity to monkeypox:  
744 Use of immunoglobulin m enzyme-linked immunosorbent assay for detection of  
745 monkeypox infection during the 2003 north American outbreak. *Clin. Diagn. Lab.*  
746 *Immunol.* **12**, 867–872 (2005).
- 747 19. Stephenson, J. Monkeypox Outbreak a Reminder of Emerging Infections



- 748 Vulnerabilities. *JAMA* **290**, 23–24 (2003).
- 749 20. Reynolds, M. G. *et al.* Spectrum of infection and risk factors for human monkeypox,  
750 United States, 2003. *Emerg. Infect. Dis.* **13**, 1332–1339 (2007).
- 751 21. European Centre for Disease Prevention and Control. Epidemiological update:  
752 Monkeypox multi-country outbreak. (2022). Available at:  
753 [https://www.ecdc.europa.eu/en/news-events/epidemiological-update-monkeypox-](https://www.ecdc.europa.eu/en/news-events/epidemiological-update-monkeypox-multi-country-outbreak)  
754 [multi-country-outbreak](https://www.ecdc.europa.eu/en/news-events/epidemiological-update-monkeypox-multi-country-outbreak). (Accessed: 14th December 2022)
- 755 22. UK Health Security Agency. Monkeypox outbreak: epidemiological overview, 4  
756 October 2022 - GOV.UK. (2022). Available at:  
757 [https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-](https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-overview/monkeypox-outbreak-epidemiological-overview-4-october-2022)  
758 [overview/monkeypox-outbreak-epidemiological-overview-4-october-2022](https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-overview/monkeypox-outbreak-epidemiological-overview-4-october-2022). (Accessed:  
759 14th December 2022)
- 760 23. Mathieu, E., Spooner, F., Dattani, S., Ritchie, H. & Roser, M. Mpox (monkeypox). *Our*  
761 *World in Data* (2022). Available at: <https://ourworldindata.org/monkeypox>. (Accessed:  
762 17th December 2022)
- 763 24. Wang, L. *et al.* Genomic annotation and molecular evolution of monkeypox virus  
764 outbreak in 2022. *J. Med. Virol.* **95**, e28036 (2022).
- 765 25. Gigante, C. M. *et al.* Multiple lineages of monkeypox virus detected in the United  
766 States, 2021–2022. *Science (80-. )*. **378**, 560–565 (2022).
- 767 26. Isidro, J. *et al.* Phylogenomic characterization and signs of microevolution in the 2022  
768 multi-country outbreak of monkeypox virus. *Nat. Med.* **28**, 1569–1572 (2022).
- 769 27. Townsend, M. B. *et al.* Humoral Immunity to Smallpox Vaccines and Monkeypox Virus  
770 Challenge: Proteomic Assessment and Clinical Correlations. *J. Virol.* **87**, 900–911  
771 (2013).
- 772 28. Nigam, P. *et al.* DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific  
773 immunity and confers protection against a lethal monkeypox challenge. *Virology* **366**,  
774 73–83 (2007).
- 775 29. Edghill-Smith, Y. *et al.* Smallpox vaccine-induced antibodies are necessary and  
776 sufficient for protection against monkeypox virus. *Nat. Med.* **11**, 740–747 (2005).
- 777 30. Earl, P. L. *et al.* Immunogenicity of a highly attenuated MVA smallpox vaccine and  
778 protection against monkeypox. (2004).
- 779 31. Stittelaar, K. J. *et al.* Modified Vaccinia Virus Ankara Protects Macaques against  
780 Respiratory Challenge with Monkeypox Virus. *J. Virol.* **79**, 7845–7851 (2005).
- 781 32. Townsend, M. B. *et al.* Retrospective Proteomic Analysis of Serum After Akhmeta  
782 Virus Infection: New Suspect Case Identification and Insights Into Poxvirus Humoral  
783 Immunity. *J. Infect. Dis.* **216**, 1505–1512 (2017).
- 784 33. Keasey, S. *et al.* Proteomic basis of the antibody response to monkeypox virus  
785 infection examined in cynomolgus macaques and a comparison to human smallpox  
786 vaccination. *PLoS One* **5**, (2010).
- 787 34. Gallwitz, S., Schutzbank, T., Heberling, R. L., Kalter, S. S. & Galpin, J. E. Smallpox:  
788 Residual antibody after vaccination. *J. Clin. Microbiol.* **41**, 4068–4070 (2003).
- 789 35. Earl, P. L. *et al.* Immunogenicity of a highly attenuated MVA smallpox vaccine and  
790 protection against monkeypox. *Nature* **428**, 182–185 (2004).
- 791 36. Davies, D. H. *et al.* Proteome-wide analysis of the serological response to vaccinia

- 792 and smallpox. *Proteomics* **7**, 1678–1686 (2007).
- 793 37. Grifoni, A. *et al.* Defining antigen targets to dissect vaccinia virus (VACV) and  
794 Monkeypox virus (MPXV)-specific T cell responses in humans. *Cell Host Microbe*  
795 1662–1674 (2022). doi:10.1016/j.chom.2022.11.003
- 796 38. Agrati, C. *et al.* Immunological signature in human cases of monkeypox infection in  
797 2022 outbreak: an observational study. *Lancet Infect. Dis.* **3099**, 1–11 (2022).
- 798 39. Karem, K. L. *et al.* Monkeypox-induced immunity and failure of childhood smallpox  
799 vaccination to provide complete protection. *Clin. Vaccine Immunol.* **14**, 1318–1327  
800 (2007).
- 801 40. Shchelkunov, S. N. *et al.* Analysis of the monkeypox virus genome. *Virology* **297**,  
802 172–194 (2002).
- 803 41. Brown, E., Senkevich, T. G. & Moss, B. Vaccinia Virus F9 Virion Membrane Protein Is  
804 Required for Entry but Not Virus Assembly, in Contrast to the Related L1 Protein. *J.*  
805 *Viol.* **80**, 9455–9464 (2006).
- 806 42. Chiu, W.-L. & Chang, W. Vaccinia Virus J1R Protein: a Viral Membrane Protein That  
807 Is Essential for Virion Morphogenesis. *J. Virol.* **76**, 9575–9587 (2002).
- 808 43. Ember, S. W. J., Ren, H., Ferguson, B. J. & Smith, G. L. Vaccinia virus protein C4  
809 inhibits NF- $\kappa$ B activation and promotes virus virulence. *J. Gen. Virol.* **93**, 2098–2108  
810 (2012).
- 811 44. Patel, D. D., Pickup, D. J. & Joklik, W. K. Isolation of cowpox virus a-type inclusions  
812 and characterization of their major protein component. *Virology* **149**, 174–189 (1986).
- 813 45. Bertran, M. *et al.* Effectiveness of one dose of MVA-BN smallpox vaccine against  
814 monkeypox in England using the case-coverage method. *UK Heal. Secur. Agency*  
815 (2022).
- 816 46. Zaeck, L. M. *et al.* Low levels of monkeypox virus-neutralizing antibodies after MVA-  
817 BN vaccination in healthy individuals. *Nat. Med.* (2022). doi:10.1038/s41591-022-  
818 02090-w
- 819 47. Hooper, J. W., Custer, D. M., Schmaljohn, C. S. & Schmaljohn, A. L. DNA vaccination  
820 with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus  
821 challenge. *Virology* **266**, 329–339 (2000).
- 822 48. Hooper, J. W. *et al.* Smallpox DNA Vaccine Protects Nonhuman Primates against  
823 Lethal Monkeypox. *J. Virol.* **78**, 4433–4443 (2004).
- 824 49. Hooper, J. W., Custer, D. M. & Thompson, E. Four-gene-combination DNA vaccine  
825 protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody  
826 responses in nonhuman primates. *Virology* **306**, 181–195 (2003).
- 827 50. Pütz, M. M., Midgley, C. M., Law, M. & Smith, G. L. Quantification of antibody  
828 responses against multiple antigens of the two infectious forms of Vaccinia virus  
829 provides a benchmark for smallpox vaccination. *Nat. Med.* **12**, 1310–1315 (2006).
- 830 51. Taub, D. D. *et al.* Immunity from Smallpox Vaccine Persists for Decades: A  
831 Longitudinal Study. *Am. J. Med.* **121**, 1058–1064 (2008).
- 832 52. Zhang, W.-H., Wilcock, D. & Smith, G. L. Vaccinia Virus F12L Protein Is Required for  
833 Actin Tail Formation, Normal Plaque Size, and Virulence. *J. Virol.* **74**, 11654–11662  
834 (2000).
- 835 53. Girgis, N. M. *et al.* Cell Surface Expression of the Vaccinia Virus Complement Control

- 836 Protein Is Mediated by Interaction with the Viral A56 Protein and Protects Infected  
837 Cells from Complement Attack. *J. Virol.* **82**, (2008).
- 838 54. Wagenaar, T. R. & Moss, B. Expression of the A56 and K2 Proteins Is Sufficient To  
839 Inhibit Vaccinia Virus Entry and Cell Fusion. *J. Virol.* **83**, 1546–1554 (2009).
- 840 55. de Haven, B. C., Gupta, K. & Isaacs, S. N. The vaccinia virus A56 protein: A  
841 multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.  
842 *Journal of General Virology* **92**, 1971–1980 (2011).
- 843 56. Berhanu, A. *et al.* Vaccination of BALB/c Mice with Escherichia coli -Expressed  
844 Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus  
845 Challenge . *J. Virol.* **82**, 3517–3529 (2008).
- 846 57. Demkowicz, W. E., Maa, J. S. & Esteban, M. Identification and characterization of  
847 vaccinia virus genes encoding proteins that are highly antigenic in animals and are  
848 immunodominant in vaccinated humans. *J. Virol.* **66**, 386–398 (1992).
- 849 58. Bell, E. *et al.* Antibodies against the extracellular enveloped virus B5R protein are  
850 mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.  
851 *Virology* **325**, 425–431 (2004).
- 852 59. Nakatake, M. *et al.* Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus  
853 Neutralization Escape while Preserving Oncolytic Function. *Mol. Ther. - Oncolytics* **14**,  
854 159–171 (2019).
- 855 60. Perdiguero, B. & Blasco, R. Interaction between Vaccinia Virus Extracellular Virus  
856 Envelope A33 and B5 Glycoproteins. *J. Virol.* **80**, 8763–8777 (2006).
- 857 61. Gilchuk, I. *et al.* Cross-Neutralizing and Protective Human Antibody Specificities to  
858 Poxvirus Infections. *Cell* **167**, 684-694.e9 (2016).
- 859 62. Chen, Z. *et al.* Characterization of Chimpanzee/Human Monoclonal Antibodies to  
860 Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a  
861 Vaccinia Virus Mouse Protection Model. *J. Virol.* **81**, 8989–8995 (2007).
- 862 63. Sang, Y. *et al.* Monkeypox virus quadrivalent mRNA vaccine induces antibody  
863 responses and cellular immunity and protects mice against Vaccinia virus. *bioRxiv*  
864 2022.11.22.517500 (2022). doi:10.1101/2022.11.22.517500
- 865 64. Mucker, E. M. *et al.* A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the  
866 Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal  
867 Rabbitpox Virus Aerosol Challenge. *J. Virol.* **96**, (2022).
- 868 65. Bloch, E. M. *et al.* The Potential Role of Passive Antibody-Based Therapies as  
869 Treatments for Monkeypox. *MBio* (2022). doi:10.1128/mbio.02862-22
- 870
- 871